Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer

HER2-positive Breast Cancer Clinical Trial

Official title:

Phase II Study of Lapatinib and Trastuzumab Followed by Concurrent Lapatinib, Trastuzumab, and Paclitaxel Followed by Surgery for Primary HER2-positive (HER2+) Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01688609
• Other study ID #: NCI-2012-01970
• Secondary ID: NCI-2012-01970CD
• Status: Completed
• Phase: Phase 2
• First received: September 16, 2012
• Last updated: March 20, 2014
• Start date: July 2012

Study information

• Verified date: December 2013
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This phase II trial studies how well giving lapatinib ditosylate together with trastuzumab, paclitaxel, and surgery works in treating patients with breast cancer. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Description:

PRIMARY OBJECTIVES:

I. To evaluate the changes in cancer stem cell (CSC) markers; % CD44 variant (CD44v)-positive tumor cells and aldehyde dehydrogenase-1 (ALDH1) positivity before and after study drug exposure and after concurrent preoperative chemotherapy.

II. To determine the pathological complete response (pCR) rate produced by lapatinib (lapatinib ditosylate) + trastuzumab followed by concurrent preoperative lapatinib, trastuzumab, and paclitaxel chemotherapy for operable human epidermal growth factor receptor 2-positive (HER2+) breast cancer.

SECONDARY OBJECTIVES:

I. To determine the cellular response rate produced by study drug exposure and/or concurrent preoperative chemotherapy.

II. To determine cutoff values of baseline ratios of phosphorylated HER2 (pHER2)/HER2, phosphorylated epidermal growth factor receptor (EGFR) (pEGFR)/EGFR, phosphorylated ERK (pERK)/ERK and phosphorylated protein kinase B (pAkt)/Akt that are associated with pCR.

III. To assess the safety and tolerability of study therapy in Japanese women.

OUTLINE:

Drug exposure: Patients receive lapatinib ditosylate orally (PO) once daily (QD) and trastuzumab intravenously (IV) over 30-90 minutes once weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.

Preoperative therapy: Patients receive lapatinib ditosylate PO QD, trastuzumab IV over 30 minutes once weekly, and paclitaxel IV over 90 minutes once weekly for 12 weeks in the absence of disease progression or unacceptable toxicity. Patients then undergo lumpectomy* or mastectomy*.

After completion of study treatment, patients are followed up for 12 weeks.

NOTE: * Patients considered to be candidates for breast-conservation therapy (BCT) are offered lumpectomy. Patients who are not considered to be candidates for BCT or who do not desire BCT undergo total mastectomy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Patients must have histologically or cytologically confirmed primary invasive breast cancer

• Primary tumor is larger than 2 cm in diameter (T2) as measured by caliper or ultrasound

• Overexpression and/or amplification of HER2 is confirmed by immunohistochemistry (IHC) 3+ or fluorescence in situ hybridization (FISH) + when IHC 2+

• Patients have not received prior therapies for breast cancer

• Patients have Karnofsky >= 70%

• Leukocytes >= 3,000/mcL

• Absolute neutrophil count >= 1,500/mcL

• Hemoglobin >= 9.0 g/dL

• Platelets >= 75,000/mcL

• Total bilirubin =< 1.5 times institutional upper limit of normal

• Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvate transaminase[SGPT]) =< 2.5 times institutional ULN

• Creatinine =< 1.5 times institutional upper limit of normal (ULN)

• Patients must have left ventricular ejection fraction (LVEF) >= 50% by multi-gated acquisition (MUGA) or echocardiography

• Patients must be able to take oral medications (i.e., no uncontrolled vomiting, inability to swallow, or diagnosis of chronic malabsorption)

• Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation as well as for at least 6 months after the last dose of trastuzumab

• Ability to understand and willingness not only for treatment but also for undergoing serial biopsies and sign a written informed consent document

• Only Japanese women are eligible for the trial

Exclusion Criteria:

• Patients who have had chemotherapy or radiotherapy

• Patients who are receiving any other investigational agents

• Patients have distal metastasis (stage IV disease)

• Patients with previous (within 10 years) or current history of malignant neoplasm except for curatively treated basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix

• Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib or other agents used in study

• Patients receiving any medications or substances that are inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) are ineligible

• Patients who have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

• Pregnant women

• Patients who have family or personal history of congenital long or short QT syndrome, Brugada syndrome, QT/QTc prolongation, or torsade de pointes

• Patients who have chronic gastrointestinal disease presenting with diarrhea (inflammatory bowel disease, malabsorption, or >= grade 2 diarrhea of any etiology at baseline)

• Patients who have neuropathy >= grade 2 of any cause

• Patients are diagnosed with inflammatory breast cancer or bilateral breast cancer

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Neoplasms
• HER2-positive Breast Cancer
• Stage II Breast Cancer
• Stage IIIA Breast Cancer

Intervention

Drug:
• lapatinib ditosylate
Given PO
• paclitaxel
Given IV

Biological:
• trastuzumab
Given IV

Procedure:
• therapeutic conventional surgery
Undergo lumpectomy or mastectomy

Other:
• pharmacological study
Correlative studies
• laboratory biomarker analysis
Correlative studies

Locations

Country	Name	City	State
Japan	Saint Luke's International Hospital	Chuo-ku	Toyko
Japan	Keio University	Shinjuku-ku	Tokyo
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Expression of ALDH1 and CD44v change in quick score Q from baseline to 6 weeks and 18 weeks	For biomarkers ALDH1 and CD44v, the change in quick score Q from baseline to 6 weeks and 18 weeks time points will be calculated for each patient. For biomarker change pre- vs. post-treatment, a paired t-test will be used to examine whether the mean quick score has decreased significantly after the treatment. Descriptive statistics (mean, standard deviation, quartiles) will be summarized for the change in quick score post-treatment. We will also graphically present the mean ALDH1 and CD44 values at baseline, at 6 week, and at 18 week time points.	From baseline to 18 weeks	No
Primary	pCR rate	The point estimate of the pCR rate will be calculated for all patients, together with its 95% confidence interval (CI).	Up to 12 weeks	No
Secondary	Cellular response rate, defined as patients with an epithelial phenotype having eradication of CTCs; patients with a mesenchymal phenotype having eradication of tumor cells; patients with a mesenchymal phenotype converting to an epithelial phenotype	Cellular response will be documented and calculated for rate in all patients.	Up to 12 weeks	No
Secondary	EGFR-mutation status of tumors and changes in the ratio of phosphorylated to nonphosphorylated HER2, EGFR, ERK, Akt, and the Ki67 and TUNEL indices before and after treatment	The EGFR mutation status will be a binary variable (yes vs. no), and the phosphorylation status of HER2 and EGFR will be a ratio variable (0-100%). The CART method to identify cut-off points for the phosphorylation ratio of molecules of interest will be used, such that ratios above the cut-off point will be considered "high phosphorylation" and ratios below the cut-off point will be considered "low phosphorylation."	From baseline to 24 weeks	No
Secondary	Safety and toxicity from the time of first treatment with lapatinib ditosylate		Up to 12 weeks after completion of study treatment	Yes